SAR.L
Sareum Holdings plc [SAR.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SAR.L Stock Summary
Top 10 Correlated ETFs
SAR.L
Top 10 Correlated Stocks
SAR.L
In the News
SAR.L Financial details
Company Rating
-
Market Cap
12.12M
Income
-7.02M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
5
Optionable
No
Shortable
Yes
Earnings
20 Mar 2024
P/E
-18.7
Forward P/E
-
PEG
-0.86
P/S
-
P/B
35.22
P/C
-
P/FCF
-12.9
Quick Ratio
1.15
Current Ratio
2.28
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.1
EPS next Y
-
EPS next Q
-
EPS this Y
46.11%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
38.91%
-
-
-
-
SMA20
30.77%
SMA50
-10.53%
SMA100
-39.29%
Inst Own
-
Inst Trans
-
ROA
-108%
ROE
-79%
ROC
-2.24%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
10.0-149.0
52W High
-88.59%
52W Low
+70%
RSI
54
Rel Volume
0.46
Avg Volume
664.96K
Volume
303.29K
Perf Week
-2.86%
Perf Month
36%
Perf Quarter
-32%
Perf Half Y
-32%
-
-
-
-
Beta
-0.785
-
-
Volatility
0.67%, 2.54%
Prev Close
-2.86%
Price
17
Change
6.25%
Company Profile
- Volume Average 664.96K
- Market Capitalization 12.12M
- Employee 5
- CEO Dr. Timothy John Mitchell Ph.D.
- Headquarters Cambridge,GB
- IPO Date 2004-10-11
-
Website
https://www.sareum.com 
Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.
